Let's talk medical research

Over the past year and a half, the traditional clinical research model of patient outreach, in-person screening, and site-based follow-up has had to adjust to drive progress while keeping patients safe. Now, with vaccines driving positivity rates down, we can begin to think about what’s next. Still, questions remain: Of all the changes made in the research industry since the beginning of the ...

Parkinson’s disease is a disorder of the central nervous system that affects movement, with symptoms such as tremor, slow movement, stiffness, and loss of balance. Current treatments come with side effects, and there is no cure. This means research is critical to developing new and better treatments for the nearly one million people in the US living with Parkinson’s disease.

What impact has COVID-19 had on our collective mental health? How has treatment been adapted to meet new needs? And what does this all mean for clinical trial participants?

Could the alternative clinical trial approaches necessitated by the COVID-19 pandemic help tip the scales towards fair access to clinical trials? In our latest whitepaper, “Decentralizing research: How reducing patient burden improves trial diversity,” we take a close look at the current state of diversity in clinical trials, then explore how the decreased participant burden of decentralized ...

By some estimations, 80% of clinical trials are delayed or closed because researchers can’t find enough patients to take part in their clinical trials. This, of course, means that trial sponsors are losing money and sites are wasting time screening ineligible patients. But, it also means that countless patients continue to wait for new and potentially better treatment options.

Living with lupus can be difficult. It’s an “invisible illness” — meaning those around you can’t see your fatigue or your muscle and joint pain or any of the many other symptoms. This can be a lonely experience, and that’s why it’s so important for people with lupus to connect with others who have the condition as well.

Are you spending time and money on clinical trial advertising that’s not delivering? It can be frustrating to put resources into spreading the word about your study, only to find that the patients who make it to your sites are not right for your trial. According to a survey Antidote conducted of 4,000+ patients, 52% of patients found out about clinical trial opportunities through an ...

An interview with Lindsey Wahlstrom-Edwards, Head of Partnerships at Antidote

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that causes scarring of the lungs. Over time, the scarring worsens and it can become difficult to breathe. IPF has no cure and limited treatment options, making clinical research especially critical. In this case study, a pharma company approached Antidote to identify 600 IPF patients who would be eligible for their study in just six ...

Does a health crisis change digital engagement behaviors? How should digital marketers respond?